Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $80.00. The company’s shares closed last Tuesday at $60.26, close to its 52-week low of $59.18.
According to TipRanks.com, Yee ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.6% and a 38.7% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Olema Pharmaceuticals, and Scholar Rock Holding.
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $73.44, which is a 22.5% upside from current levels. In a report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $85.00 price target.
Gilead Sciences’ market cap is currently $75.56B and has a P/E ratio of 12.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
Read More on GILD:
- Eaton (ETN) Receives a Buy from Jefferies
- Analysts Have Conflicting Sentiments on These Consumer Goods Companies: AutoZone (AZO), Nordstrom (JWN) and CarPartscom (PRTS)
- Elastic (ESTC) Gets a Buy Rating from Monness
- Monness Remains a Buy on Salesforce (CRM)
- UBS Thinks JPMorgan Chase & Co.’s Stock is Going to Recover